Search

Introduccion Se comparan dos pruebas para detectar anticuerpos antimicelio en pacientes con candidiasis invasiva: una nueva tecnica comercializada (Candida albicans IFA IgG) y la tecnica de inmunofluorescencia indirecta tradicionalmente empleada para la deteccion de anticuerpos contra la fase micelial de C. albicans (anticuerpos antimicelio) Metodos Mediante dos tecnicas de inmunofluorescencia indirecta se estudiaron retrospectivamente un total de 172 sueros de 51 pacientes clasificados en dos grupos: el grupo I incluia 123 sueros de 32 pacientes con candidiasis invasiva y el grupo II, utilizado como control, comprendia 49 sueros de 19 pacientes sin evidencia de infeccion por Candida Resultados El 84,4% de los pacientes con candidiasis invasiva (grupo I) presentaron titulos de anticuerpos antimicelio ≥ 1:160 con la prueba Candida albicans IFA IgG, mientras que el 78,1% lo hicieron con la tecnica tradicional. Ambas tecnicas presentaron una alta correlacion al ser comparadas entre si (R2= 0,9512 por pacientes; R2= 0,8986 por sueros). Utilizando un titulo de corte de anticuerpos antimicelio ≥ 1:160 para el diagnostico de la candidiasis invasiva, la prueba Candida albicans IFA IgG presento una sensibilidad del 84,4% y una especificidad del 94,7%, mientras que la tecnica tradicional presento una sensibilidad del 78,1% y una especificidad del 100%. Conclusion. La prueba comercializada Candida albicans IFA IgG es muy similar a la prueba tradicionalmente empleada para la deteccion de anticuerpos antimicelio, permitiendo un diagnostico mas rapido y sencillo de la candidiasis invasiva en los laboratorios de microbiologia hospitalarios

Human T-lymphotropic virus type I (HTLV-I), is the pathogenic agent of adult T-cell leukemia-lymphoma (ATLL), which always shows monoclonal HTLV-I provirus DNA integration. HTLV-I is rarely associated with B-cell disorders. The gen Tax of a human T-cell leukemia virus type I (HTLV-I) induces the expression of several cellular genes that are involved in T cell activation and proliferation. In the current study was to analyze prospectively HTLV-I proviral DNA presence in peripheral blood mononuclear cells (PBMCs) in patients with leukemia or lymphoma which are different to ATLL. Following this pattern we have studied in 61 patients with T and B-cell malignancies the presence of the virus HTLV-I on the during our service between April 2004 and May 2006. A real time PCR assay using SYBR Green intercalation was established. Primer and hybridization probes targeting tax region were standardized against MT2 cell line DNA for HTLV-I. The assay reliably detected a single copy of HTLV-I proviral genome in DNA from 1X106 PBMCs. Also included for each sample the HLA-DQ alpha gene (a measure of genomic DNA), We have detected the presence of HTLV-I in five patients: 2 patients with B-CLL (lymphocytes count: 1.3 x 109/L and 16,8 respectly), one patient with T-ALL CD4 and CD8 positive; other with NHL and one with B-ALL Ph+. As an interesting data, one of the patients with B-CLL presented as complication a immune thrombocytopenia after Fludarabine therapy. Two patients were died and the two cases with B-CLL show stable sickness. Only the patient with T-ALL achieved complete remission after chemotherapy. In conclusion, we have detected on our series, in a unsuspected way, the presence of HTLV-I on some of the patients with lymphoid malignancies, which are different to the ATLL, showing in these cases an atypical clinic course. After knowing the repercussion of HTLV-I over the immune competition of the infected patients it seems suggestive speculate on the possible implication of the virus in a deterioration of the immunity favouring the progress of neoplasia and/or a greater propensity to infections and immunological upheavals, like the observed ones in our series.